Rare diseases
Investigational molecules
Locations
3350 Riverwood Parkway Southeast # 1900, 30339-2066, United States
Research activity is centered on pulmonary arterial hypertension, with clinical interest in adult WHO Group 1 PAH and treatment strategies used alongside established background therapy. The sponsor’s work in this area reflects a focus on the management of pulmonary vascular disease and related cardiopulmonary impairment.
The clinical program is aligned with therapeutic development in rare cardiovascular disorders affecting pulmonary circulation and right heart function.
Inhibikase Therapeutics Inc. runs clinical trials in conditions such as Pulmonary arterial hypertension, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
